June 25, 2020 11:23 AM EDTUpdated June 26, 07:28 AM
Coronavirus

Covid-19 roundup: Mod­er­na en­lists Catal­ent as man­u­fac­tur­ing part­ner, se­cur­ing fill-fin­ish ca­pac­i­ty for the first 100M dos­es

Amber Tong

With Phase III tri­als now out­lined, lock­ing in a net­work of pro­duc­tion part­ners ap­pears to be top of mind for the lead­ing Covid-19 vac­cine de­vel­op­ers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times